Pharmaceuticals · PH-08 · Quality control laboratory and data integrity

A result must not change. If it does, the change must leave a trace.

When moving to EU GMP, laboratory data integrity is examined separately. The state reimburses half of the certification-related consultancy costs, but the laboratory process remains the company's own responsibility.

Platform: Plant Pulse

58

Pharmaceutical manufacturers holding national GMP.1

$50,000

Maximum reimbursable amount (50%) for foreign consultancy services on EU GMP / FDA GMP.2

55

Countries to which Uzbek pharmaceutical products are exported.1

The laboratory logbook is the inspector's favourite document.

Who it is for

Head of QC
Results.
QA
Batch release.
IT
System validation.
Export
Buyer requirements.

Where the problem lies

  • Results in Excel

    Spreadsheets have no audit trail.

  • Instrument data

    Results are transcribed manually from instruments.

  • Sample traceability

    Samples are not linked to batches.

  • Deviations

    Out-of-specification investigations are on paper.

How the loss is calculated

Inspection observationsobservations per inspection × corrective action cost per observation
Repeat testingrepeat tests per month × cost per test
Release delaydelay days per batch × delayed batches per month
Exportlost export market revenue per year

Calculate with your data

Holding Cost of Batches Awaiting QC Release

This calculator estimates the monthly cost of finished batches waiting for QC laboratory results and the release decision.

Use spaces for thousands and a dot or comma for decimals. Use the same currency throughout.

Values stay in this page and are not sent to the server.

Scenario estimate

0 / 6 values entered

Enter your operating figures to see the estimate.

Results are estimates, not guaranteed savings. The target lead time is user-supplied and is not presented as attainable. This calculation does not confirm GMP/GDP compliance, inspection outcomes or validation status. Capital cost is based on batch cost, not selling price. Do not include capital cost in the storage cost input, or it will be double counted. Firm timelines and prices can only be assessed after an audit and based on measured data.

Formulas and assumptions

This calculator estimates the monthly cost of finished batches waiting for QC laboratory results and the release decision. It covers tied-up capital, based on batch cost, and quarantine storage cost. It compares your current release lead time with a target lead time that you define. The calculation period is one month. Retests, remediation of inspection findings, lost exports and lost sales are not included. Enter all values from your own site data.

Average capital tied up awaiting release (current)
Batches per month × 12 ÷ 365 days gives batches per day; this is multiplied by the current release lead time (days) and the cost per batch. The result is the average value of batches in quarantine at any time. It is stock value, not a cost.
Monthly holding cost (current lead time)
Batches per month × current lead time (days) × [cost per batch × annual rate % ÷ 100 ÷ 365 + daily storage cost per batch].
Monthly holding cost (target lead time)
Same calculation as for the current lead time, using your target lead time (days): batches per month × target days × [cost per batch × rate % ÷ 100 ÷ 365 + daily storage cost].
Estimated monthly difference between current and target lead time
Batches per month × (current − target lead time, days) × daily cost per batch. A negative result is shown as 0. This is an estimate, not guaranteed savings.

Facts and global practice

  • Presidential meeting

    All 58 manufacturers hold national GMP and must align with EU GMP; products are exported to 55 countries.1

  • yuz.uz

    From 1 June 2026, 50% of the cost of foreign consultancy services for EU GMP, US FDA GMP and WHO prequalification is reimbursed, capped at $50,000.2

  • anhor.uz

    Only 12% of companies hold an international GMP certificate.3

No statistics were found on Uzbek inspections related to data integrity.

Sample, result and batch in one trail

The sample is linked to the batch, the result is entered from the instrument or via a form, every change is kept in the audit trail, and deviations are logged automatically.

  1. 01Sample
    • Batch
    • Time
    • Location
  2. 02Test
    • Instrument
    • Result
    • Specification
  3. 03Deviation
    • OOS
    • Investigation
    • Decision
  4. 04Release
    • QA
    • Audit trail
    • Archive

Modules

The current maturity level is shown next to each module.

Sample and result logWith audit trailEngineering capability
Deviation (OOS) logElectronicEngineering capability
Batch linkage (WMS)StatusCommercially available
Full LIMSPartnerIn development

How we start

  1. 01

    Data integrity audit

    Laboratory.

    Outcome: Gaps.

  2. 02

    Pilot

    One test type.

    Outcome: Audit trail.

  3. 03

    Scale-up

    All tests.

    Outcome: Complete log.

  4. 04

    Validation

    With a partner.

    Outcome: Inspection readiness.

What is measured

Manual transcriptionShareAudit
OOS casesCountLog
Result turnaround timeDaysSystem
Audit trail completeness%System

What is needed to start

  • Head of QC
  • List of tests
  • List of instruments
  • Validation requirements

What we do not promise

  • Exact timeline and price without an audit
  • GMP/GDP certification or inspection outcome
  • Approving validation documents ourselves
  • Unmeasured results
  • Full LIMS (partner)

Self-check

  1. Are results stored in a system?
  2. Does every change leave a trace?
  3. Do instrument results arrive automatically?
  4. Are samples linked to batches?
  5. Is the OOS log electronic?
  6. Are user permissions restricted?
  7. Is the archive retention period defined?
  8. Has a reimbursement application been submitted?
  9. Has a consultant been selected?
  10. Is there a responsible person?

Laboratory audit

We review laboratory data integrity and identify inspection risks.

  • Map of break points
  • Pilot plan
  • Implementation fee and monthly subscription

Sources

  1. Presidential videoconference: expanding production in the pharmaceutical industry. president.uz, 05.03.2026.
  2. Decree of 05.03.2026 on incentives for the pharmaceutical sector: 2026 targets. yuz.uz, 2026.
  3. “12% of pharmaceutical companies in Uzbekistan meet international standards.” anhor.uz.